Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

303
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
303
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

276
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
276
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Clinical Trials01:16

Clinical Trials

10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.9K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

364
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
364
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

353
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
353

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Natural History of C3 Glomerulopathy and Immune Complex-Associated Membranoproliferative Glomerulonephritis in Children.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Global trends and geographic variations of hypertension in childhood and adolescence 1990-2021: a systematic analysis of the Global Burden of Disease Study 2021.

Clinical hypertension·2026
Same author

Blood Pressure Assessment Across the Lifespan: Improving Clinical Research and Clinical Practice: A National Heart, Lung, and Blood Institute Workshop Report.

Journal of the American College of Cardiology·2026
Same author

Ambulatory arterial stiffness index among children and adolescents with chronic kidney disease a report from the Chronic Kidney Disease in Children Study.

Research square·2026
Same author

Contemporary Treatment Responses of Recurrent Focal Segmental Glomerulosclerosis or Steroid Resistant Nephrotic Syndrome in Children after Kidney Transplantation: Phase 2 of a Multicenter Electronic Health Record Data Analysis.

Research square·2026
Same author

Electroencephalography during acute painful procedures in neonates: a scoping review.

Pain reports·2026

Related Experiment Video

Updated: Feb 23, 2026

Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

8.3K

Enhancing clinical trial development for pediatric kidney diseases.

H William Schnaper1, Joseph T Flynn2, Coleman Gross3

  • 1Department of Pediatrics (Kidney Diseases), Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Pediatric Research
|August 31, 2017
PubMed
Summary

Pediatric clinical trials face challenges due to clinician workload and limited patient numbers. The American Society of Pediatric Nephrology Therapeutics Development Committee (TDC) aims to improve trial development by fostering collaboration among stakeholders in pediatric kidney disease research.

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.8K
Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions
08:06

Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions

Published on: July 2, 2020

5.1K

Related Experiment Videos

Last Updated: Feb 23, 2026

Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

8.3K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.8K
Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions
08:06

Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions

Published on: July 2, 2020

5.1K

Area of Science:

  • Pediatric Nephrology
  • Clinical Trial Management
  • Healthcare Collaboration

Background:

  • Conducting clinical trials in pediatric nephrology is challenging due to high clinical demands on specialists and a limited patient population.
  • These constraints hinder the development and execution of essential research studies for children with kidney disease.

Purpose of the Study:

  • To establish the American Society of Pediatric Nephrology Therapeutics Development Committee (TDC).
  • To identify stakeholders involved in pediatric kidney disease clinical trials.
  • To foster effective partnerships for successful clinical trial development and execution.

Main Methods:

  • The article discusses the rationale, structure, and function of the TDC.
  • It outlines the committee's progress toward its established goals.
  • Insights gained from the TDC's experience are presented.

Main Results:

  • The TDC was formed to address challenges in pediatric nephrology clinical trials.
  • The committee focuses on stakeholder identification and partnership development.
  • Progress and insights are being generated to improve trial conduct.

Conclusions:

  • The TDC provides a framework for overcoming obstacles in pediatric clinical research.
  • Effective collaboration is crucial for advancing pediatric nephrology trials.
  • The TDC's model offers valuable lessons for other pediatric subspecialties facing similar research challenges.